Diabetes

  • Medtronic's MiniMed 780G
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic wins expanded FDA label for 780G insulin pump

    The 510(k) decision clears the device for use with ultra-rapid-acting insulins from Eli Lilly and Novo Nordisk.

    By • Feb. 5, 2026
  • A person on a stationary bike wears a small, white patch on their upper arm.
    Image attribution tooltip
    Permission granted by Abbott Laboratories
    Image attribution tooltip

    Abbott receives FDA warning letter over Freestyle Libre CGMs

    Abbott needs to conduct more performance testing to ensure its FreeStyle Libre devices are accurate, FDA inspectors found.

    By • Feb. 3, 2026
  • Boston Scientific's Farapulse pulsed field ablation device. Explore the Trendline➔
    Image attribution tooltip
    Permission granted by Boston Scientific
    Image attribution tooltip
    Trendline

    New medical devices are reshaping the medtech industry

    From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.

    By MedTech Dive staff
  • A person sits on a couch with a white patch on their upper arm and a rectangular device with a screen on their hip.
    Image attribution tooltip
    Courtesy of Beta Bionics
    Image attribution tooltip

    Beta Bionics receives FDA warning letter

    The letter, which the FDA has not yet published, does not affect Beta Bionics’ ability to market, manufacture or distribute products, the company said.

    By • Feb. 2, 2026
  • A black reader is shown on top of a phone with a blood glucose reading.
    Image attribution tooltip
    Permission granted by Senseonics
    Image attribution tooltip

    Senseonics wins CE mark for one-year CGM

    The company is hiring sales reps and transitioning staff from its former partner to support launches in Germany, Italy, Spain and Sweden.

    By • Jan. 30, 2026
  • Modern glass and metal office building with a reflective blue-tinted facade, set against a clear blue sky. In the foreground, a large black and white sign reads “Abbott” with the company’s stylized logo and the number “645.” The area has neatly cut grass and a few small trees.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Abbott posts Q4 sales below expectations

    Pricing challenges in Abbott’s nutrition business and lower than expected sales of continuous glucose monitors drove down the company’s shares.

    By • Jan. 22, 2026
  • A person sits on a ledge with their legs in the water and eats. A patch is on their arm and a pen is on the ground next to food.
    Image attribution tooltip
    Permission granted by Medtronic
    Image attribution tooltip

    Medtronic gets FDA clearance for smart insulin pen app

    The app pairs Medtronic’s smart insulin pens with a sensor made by Abbott.

    By • Jan. 13, 2026
  • A person holds a phone, wearing a white patch on their forearm and an insulin pump on their hip.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic’s diabetes spinoff MiniMed files for IPO

    MiniMed is pitching the breadth of its portfolio as an advantage over more focused rivals such as Dexcom and Insulet.

    By • Dec. 22, 2025
  • A sign for the FDA is shown in front of the headquarters building in Silver Spring, Maryland.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA pilots allowing digital health devices access to CMS payment program

    Companies can ask the FDA to waive premarket authorization and investigational device requirements while they collect real-world data in a CMS program.

    By • Dec. 10, 2025
  • The exterior of Medtronic's Minnesota operational headquarters is shown along with its reflection in a pool of water.
    Image attribution tooltip
    Courtesy of Medtronic
    Image attribution tooltip

    Medtronic changes investor relations leadership ahead of diabetes spinout

    Ryan Weispfenning has elected to take up the challenge of creating and leading the investor relations function at the planned new diabetes company.

    By • Dec. 9, 2025
  • A person stands outside wearing a small, square device with a cord on their belt.
    Image attribution tooltip
    Permission granted by Medtronic
    Image attribution tooltip

    Medtronic launches insulin delivery system with Abbott-made sensor

    The partnership is the first time Medtronic has integrated its insulin pumps with a sensor developed outside of the company.

    By • Dec. 3, 2025
  • CMS Administrator Dr. Mehmet Oz speaks at an Aspen Institute event.
    Image attribution tooltip
    Permission granted by Aspen Institute
    Image attribution tooltip

    CMS finalizes competitive bidding changes to diabetes devices

    AdvaMed supported adjustments made from a draft version but still has concerns about the impact on patient access.

    By • Dec. 1, 2025
  • A person wearing a white, round patch on their upper arm holds a phone.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    OIG report finds Medicare overpaying for CGMs and supplies

    The CMS could use its competitive bidding program to address price concerns, after payments for the devices swelled over five years, the government watchdog said.

    By • Nov. 26, 2025
  • A person on a stationary bike wears a small, white patch on their upper arm.
    Image attribution tooltip
    Permission granted by Abbott Laboratories
    Image attribution tooltip

    Abbott issues correction for millions of glucose sensors

    The problem applies to Abbott’s Libre 3 and Libre 3 Plus sensors. The company said it has received reports of 736 severe adverse events and seven deaths.

    By • Nov. 24, 2025
  • Professional photo of Ashley McEvoy
    Image attribution tooltip
    Permission granted by Insulet
    Image attribution tooltip

    Insulet unveils plans for new diabetes devices

    The medtech firm plans to launch its next flagship patch-pump in 2027, and its first fully closed loop system for Type 2 diabetes in 2028.

    By • Nov. 24, 2025
  • A picture of five Ōura smart rings against a gold background.
    Image attribution tooltip
    Courtesy of Ōura
    Image attribution tooltip

    Tidepool, Ōura partner on diabetes research

    The collaboration will pair biometric data from the Oura ring with information from glucose sensors and insulin pumps.

    By • Nov. 6, 2025
  • CMS Administrator Dr. Mehmet Oz speaks at an Aspen Institute event.
    Image attribution tooltip
    Permission granted by Aspen Institute
    Image attribution tooltip

    Legislators object to proposed CMS payment changes for diabetes tech

    In a letter to CMS Administrator Mehmet Oz, diabetes caucus leaders raised concerns that the agency’s proposals will reduce access to glucose monitors and insulin pumps.

    By • Nov. 4, 2025
  • An oval shaped device on a patch says Dexcom G6.
    Image attribution tooltip
    Courtesy of Dexcom
    Image attribution tooltip

    Dexcom recalls G6 CGM app over software problem

    A software defect could cause the app to terminate, resulting in missed alerts or alarms. Dexcom required users to download an update.

    By • Nov. 4, 2025
  • A person smiles and poses for a professional photo.
    Image attribution tooltip
    Permission granted by Biolinq
    Image attribution tooltip
    Q&A

    Biolinq’s Jared Tangney on making CGMs unintimidating

    The chief technology officer and co-founder explained the technology and design choices that went into Biolinq’s device, which he hopes will be easier to use than other glucose monitors.

    By • Oct. 20, 2025
  • The Dexcom G7 Continuous Glucose Monitoring (CGM) System
    Image attribution tooltip
    Courtesy of Dexcom
    Image attribution tooltip

    Dexcom faces proposed class action suit over G7 CGM problems

    The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

    By • Oct. 20, 2025
  • Modern glass and metal office building with a reflective blue-tinted facade, set against a clear blue sky. In the foreground, a large black and white sign reads “Abbott” with the company’s stylized logo and the number “645.” The area has neatly cut grass and a few small trees.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Abbott CEO: ‘We’re right on time’ to the PFA party

    As competitors have launched their first pulsed field ablation devices in the U.S., Abbott CEO Robert Ford told investors that the company is not just playing defense.

    By • Oct. 15, 2025
  • A close-up shot of a woman's hands, handling a syringe of insulin.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Revvity, Sanofi team on early Type 1 detection; Kihealth raises funds for diabetes test rollout

    The Sanofi partnership will support clinical validation and regulatory submissions for Revvity’s new assay. Elsewhere, Kihealth raised $5 million in seed funding to launch its early detection test.

    By • Oct. 6, 2025
  • A person wears a small, white round sensor on their forearm.
    Image attribution tooltip
    Courtesy of Biolinq
    Image attribution tooltip

    Biolinq gets FDA de novo nod for intradermal glucose sensor

    The device, called Biolinq Shine, is indicated for people with Type 2 diabetes who don’t depend on insulin.

    By • Updated Sept. 29, 2025
  • Professional photo of Que Dallara
    Image attribution tooltip
    Permission granted by Medtronic
    Image attribution tooltip
    Q&A

    Que Dallara on Medtronic’s diabetes spinoff, pipeline and Abbott partnership

    Dallara, president of Medtronic’s diabetes business, discussed the segment’s turnaround and why she sees a benefit in becoming a standalone firm.

    By • Sept. 25, 2025
  • Professional photo of Flavia Pease
    Image attribution tooltip
    Retrieved from Insulet on September 16, 2025
    Image attribution tooltip

    Insulet names new CFO; Dexcom CEO on leave

    Flavia Pease will take over as Insulet’s CFO on Sept. 30. Elsewhere, outgoing Dexcom CEO Kevin Sayer is taking a medical leave of absence.

    By • Sept. 16, 2025
  • A black reader is shown on top of a phone with a blood glucose reading.
    Image attribution tooltip
    Permission granted by Senseonics
    Image attribution tooltip

    Senseonics inks deal to bring CGM commercialization back in-house

    BTIG analysts said Senseonics is doubling down on its belief an inflection point in patient demand is imminent, but the company will need a large sales force to win market share.

    By • Sept. 8, 2025